Please type a plus sign (+) inside this box	 +	
VF F V - /	1 1	

PTO/SB/05 (11-00) Approved for use through 10/31/2002. OMB 0651-0032

U..S. Patent and Trademark Office, U.S DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number 38-21(51892)B Attorney Docket No. UTILITY Bougri, Oleg V. First Inventor PATENT APPLICATION Ø NUCLEIC ACID MOLECULES AND OTHER MOLECULES Title TRANSMITTAL ASSOCIATED WITH PLANTS (Only for new nonprovisional applications under 37 CFR 1.53 (b)) EK089244633US Express Mail Label No. Assistant Commissioner for Patents APPLICATION ELEMENTS ADDRESS TO: Box Patent Application See MPEP chapter 600 concerning utility patent application contents Washington, DC 20231 CD-ROM or CD-R in duplicate, large table or Fee Transmittal Form (e.g., PTO/SB/17) 7. Computer Program (Appendix) (Submit an original and a duplicate for fee processing) 8. Nucleotide and/or Amino Acid Sequence Submission Applicant claims small entity status. (if applicable, all necessary) X Specification [Total Pages Computer Readable Form (CFR) (preferred arrangement set forth below) Specification Sequence Listing on: - Descriptive title of the invention - Cross References to Related Applications i. | **X** CD-ROM or CD-R (2 copies); or - Statement Regarding Fed sponsored R and D - Reference to sequence listing, a table, or a computer program listing appendix - Background of the Invention Statement verifying identity of above copies - Brief Summary of the Invention ACCOMPANYING APPLICATION PARTS - Brief Description of the Drawings (if filed) - Detailed Description Assignment Papers (cover sheet_document(s)) 9. - Claim(s) - Abstract of the Disclosure 37 CFR 3.73(b) Statement Power of 10. Attorney (when there is an assignee) Drawing(s) (35 USC 113) [Total Sheets **English Translation Document** (if applicable) 20 Information Disclosure Copies of IDS Total Pages Oath or Declaration 12. Statement (IDS)/PTO-1449 Citations Newly executed (original or copy) Preliminary Amendment 13. Copy from a prior application (37 CFR 1.63(d)) Return Receipt Postcard (MPEP 503) (for continuation/divisional with Box 17 completed 14. (should be specifically itemized) Certified Copy of Priority Document (s) **DELETION OF INVENTOR(S)** 15. (if foreign priority is claimed) Signed statement attached deleting inventor(s) named in the prior application, see 37 CFR Request and Certification under 35 U.S.C. 122 1.63(d)(2) and 1.33(b). 16. (b)(2)(B)(i). Applicant must attach form PTO/SB/35 or its equivalent. Application Data Sheet. See 37 CFR 1.76 17. Other: 18. If a CONTINUING APPLICATION, check appropriate box and supply the requisite information below and in a preliminary amendment or in an Application Data Sheet under 37 CFR 1.76: of prior application No: Divisional Continuation-in-part (CIP) Continuation Group/Art Unit. Prior Application Information. Examiner For CONTINUATION OR DIVISIONAL APPS ONLY. The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 5b, is considered a part of the disclosure of the accompanying continuation or divisional application and is hereby incorporated by reference The incorporation can only be relied upon when a portion has been inadvertently omitted from the submitted application parts. 19. CORRESPONDENCE ADDRESS Correspondence address below Ansert Customer No. or attach Bar Code Customer Number or Bar Code Label Lawrence M. Lavin, Jr. Name Patent Department, E2NA; Monsanto Company Address 800 N. Lindbergh Boulevard Missouri ZIP CODE 63167 City St. Louis State USA (314) 694-3602 FAX (314) 694-1671 Telephone Country 30768 Name (Print/Type) Lawrence M. Lavin, Jr. Registration No. (Attorney/Agent) Signature Jr. Date: I werence M Lowin

Burden Hour Statement This form is estimated to take 2 hours to complete. Time will vary depending pon the needs of the individual cases. Any comments on the amount of time you required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO. Assistant Commissioner for Patents, Box Patent Application, Washington, DC 20231.

U..S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

<u>—</u> ი				L				mplete if Known		
FEE '	TRANSN	ITTAL		App	licatio	n Num				
FEE TRANSMITTAL for FY 2001 Parant for gre-subject to applied revision					ng Dat					
			First Named Inventor Examiner Name			entor	Bo	ugri, Oleg V.		
Patent	fee are subject to annu	al revision.			miner up Art					
TOKAL AMOUN	T OF PAYMENT	(\$) 710				Docket :	No.	39	8-21(51892)B	
METHO	DD OF PAYMENT	(check one)							-	
	oner is hereby authorized to		3. AT	DITIO	NAL	FEES				***
I. IAI	and credit any overpaymen	ts to:	i	Entity Fee	Small Fee Code			Fee Description	1	Fee Pa
Account Number	13-412	5	105	130	205	65	Surcharge	- late filing fee or oath		0
Deposit			127	50	227	25	Surcharge	e - late provisional filin	g fee or cover she	e -
Account Name			139	130	139	130	Non-Engli	ish specification	-	0
X Charge Any Aunder 37 CFR	dditional Fee Required 1.16 and 1.17		147	2,520	147	2,520	_	a request for ex part ree	xamination	0
Applicant clair	ns small entity status.		112	920*	112	1,840*	-	g publication of SIR pri-		ction 0
See 37 CFR 1.	•		113	1,840*	113	1,840*		g publication of SIR after		
2. Payment E			115	110	215	55		n for reply within first r		0
Check		oney Other	116	380	216	190		n for reply within secon		0
FEE CA	LCULATION		117	870	217	435		n for reply within third		0
1. BASIC FILING F	EE		118	1,360	218	680		n for reply within fourth		0
Large Entity Sm:	•		128	1,850	228	925		n for reply within fifth 1		0
Fee Fee Fe Code (\$) Cod		ription	119	300	219	150	Notice of	• •	monu	0
101 710 2	201 355 Utility filing	g fee 710	120	300	220	150		orief in support of an ap	neal	0
106 320 2	206 160 Design filir		120	260	221	150	•	for Oral hearing	pear	0
107 490 2	07 245 Plant filing 08 355 Reissue filir		138		138		-	o institute a public use p	orogodina	0
108 710 2	08 355 Reissue filir 14 75 Provisional		l	1,510		1,510				0
114 150 2	SUBTOTAL (<u> </u>	140	110	240	55		to revive - unavoidable		0
: .	·		141	1,210	241	605		to revive - unintentional		
2. EXTRA CLAIM F		Fee from	142	1,210	242	605	-	sue fee (or reissue)		0
je, –	Extra Claims 9 -20** = -11 X	$\begin{array}{ccc} \text{below} & \text{Fee Paid} \\ 18 & = & 0 \end{array}$	143	430	243	215	Design i			0
1	3 - 3** = 0	` - -	144	430	243	215	Plant iss			0
Multiple Dependent		270 = 0	122	130	122	130		s to commissioner		0
** or number previously p	aid, if greater; For reissues	s, see below	123	50	123	50		sing under 37 CFR 1.17		0
•	Entity For For descrip	tion	126	240	126	240		sion of information Disc		<u> </u>
Fee Fee Fee Code (\$) Code	Fee Fee descrip (\$)	LIUII	581	40	581	40	Record (times	ling each patent assignr s number of properties)	ment per property	0
103 18 203	9 Claims in exc		146	690	246	345	Filing a (37 C	submission after final FR §1 129(a))	rejection	0
102 80 202	•	claims in excess of 3	149	690	249	345	For each	n additional invention to		0
104 270 204 109 80 209		ndent claims, if not paid dependent claims	179	690	279	345		FR §1.129(b)) t for continued Examina	ation (RCE)	0
	over original	patent					1		` ,	
110 18 210	9 ** Reissue o and over orig	laims in excess of 20 ginal patent	169	900	169	900	Request of a d	t for expedited examinatesign application	tion	0
	SUBTOTAL (2) (\$) 0	Othe	r fee (spec	ify)					
** or number previous	ly paid, if greater; For rei	ssues, see abive	*Redu	iced by Ba	asıc Fılir	ng Fee Pa	id	SUBTO'	TAL (3)	(\$)
SUBMITTED BY			-						Complete	(if applica
Name (Print/Type)	Lawrence M. Lavin,	Jr.	R	egistrati	on No.	(Attorne	y/Agent)	30768	Telephone	(314) 694-3
(-) F - /	Low sence M. La					•	g. No. 4		Date:	04/18/2

Docket No. 38-21(51892)B Inventors: Oleg V. Bougri et al.

Page 1 of 3

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Oleg V. Bougri et al.

Appln. No.: To Be Assigned

Filed:

For:

Nucleic Acid Molecules and Other

Molecules Associated With Plants

Art Unit:

To Be Assigned

Examiner:

To Be Assigned

Atty. Docket: 38-21(51892)B

I hereby verify this transmittal together with the patent application referred to below is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 Express Mail Label No. EK089244633US on the date indicated and is addressed to: Commissioner for Patents, Washington, D.C. 20231

Jian S. Zhou

Registration No. 41, 422

Date: Apri/18, 200/

TRANSMITTAL OF NON-PROVISIONAL PATENT APPLICATION

Commissioner for Patents

Box Patent Application

Washington, D.C. 20231

Sir:

Transmitted herewith for filing under 37 C.F.R. §1.53(b) is the complete patent application of:

Nucleic Acid Molecules and Other Molecules Associated with Plants

Inventors: Oleg V. Bougri

Joseph R. Byrum

Robert C. De La Pena



Thomas J. La Rosa Hridayabhiranjan Shukla

The following documents are forwarded herewith for appropriate action by the U.S. Patent and Trademark Office:

- 1. Utility Patent Application Transmittal (PTO/SB/05);
- 2. Form PTO/SB/17 (in duplicate);
- 3. U.S. Utility Patent Application entitled:

Nucleic Acid Molecules and Other Molecules Associated with Plants

and naming as inventors:

Oleg V. BOUGRI, Joseph R. BYRUM, Robert C. DE LA PENA, Thomas J. LA ROSA and Hridayabhiranjan SHUKLA

the application consisting of:

- a. A specification containing:
 - (i) 68 pages of a description prior to the claims;
 - (ii) _____ page of claims (9 claims); and
 - (iii) a one (1) page abstract;
- 4. The computer readable form (CRF) containing the sequence listing information;
- 5. 2 CD-Rs (Copy 1, Copy 2) containing the Sequence listing;
- 6. Statement regarding Sequence Submission;
- 7. Combined Declaration and Power of Attorney, executed by inventor Oleg V. Bougri (4 pages);
- Combined Declaration and Power of Attorney, executed by inventor Joseph R.
 Byrum (4 pages);

9. Combined Declaration and Power of Attorney, executed by inventor Robert C. De La Pena (4 pages);

- 10. Combined Declaration and Power of Attorney, executed by inventor Thomas J. La Rosa (4 pages);
- 11. Combined Declaration and Power of Attorney, executed by inventor Hridayabhiranjan Shukla (4 pages);
- 12. Form PTO/SB/35;
- 13. An Information Disclosure Statement;
- 14. Form PTO-1449 (1 page), with 8 accompanying documents; and
- 15. Two (2) return postcards

It is respectfully requested that the two attached prepaid postcards be stamped with the filing date and unofficial application number and returned as soon as possible.

Respectfully submitted,

Lawrence M. Lavin, Jr., Esq (Reg. No. 30,768)

Jian S. Zhou (Reg. No. 41,422)

Enclosures

Date: April 18, 200/

Patent Department, E2NA Monsanto Company 800 N. Lindbergh Boulevard

St. Louis, MO 63167 Tel: 636-694-3602 Fax: 636-694-1671

U..S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

REQUEST AND CERTIFICATION **UNDER**

35 U.S.C. 122(b)(2)(B)(i)

Oleg V. Bougri First Named Inventor NUCLEIC ACID MOLECULES AND OTHER MOLECULES ASSOCIATED Title WITH PLANTS 38-21(51892)B Attorney Docket No.

I hereby certify that the invention disclosed in the attached application has not and will not be the subject of an application filed in another country, or under a multilateral agreement, that requires publication at eighteen months after filing. I hereby request that the attached application not be published under 35 U.S.C. 122(b).

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

April 18, 2001

Typed or printed name

This request must be signed in compliance with 37 CFR 1.33(b) and submitted with the application upon filing.

Applicant may rescind this nonpublication request at any time. If applicant rescinds a request that an application not be published under 35 U.S.C. 122(b), the application will be scheduled for publication at eighteen months from the earliest claimed filing date for which a benefit is claimed.

If applicant subsequently files an application directed to the invention disclosed in the attached application in another country, or under a multilateral international agreement, that requires publication of applications eighteen months after filing, the applicant **must**notify the United States Patent and Trademark Office of such filing within forty-five (45) days after the date of the filing of such foreign or international application. Failure to do so will result in abandonment of this application (35 U.S.C. 122(b)(2)(B)(iii)).

Burden Hour Statement This collection of information is required by 37 CFR 1.213(a). The information is used by the public to request that an application not be published under 35 U.S.C. 122(b) (and the PTO to process that request). Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This form is estimated to take 6 minutes to complete. This time will vary depending pon the needs of the individual cases. Any comments on the amount of time you required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, 20231 DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Box Patent Application, DC Washington, DC 20231.

The first field for the first term of the first terms of the first ter

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Oleg V. Bougri et al.

Art Unit:

To be assigned

Appln. No.: To Be Assigned

Examiner:

To be assigned

Filed:

Atty. Docket: 38-21(51892)B

For:

Nucleic Acid Molecules And Other Molecules Associated With Plants

I hereby verify this Statement together with the patent application referred to above is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 Express Mail Label No.EK089244633US on the date indicated and is addressed to: Commissioner for Patents, Washington, D.C. 20231

Jian S. Zhou

Registration No. 41, 422

Statement Regarding Sequence Submission

Assistant Commissioner for Patents Washington, DC 20231

Box Patent Application

Sir:

In accordance with 37 C.F.R. § 1.821(f), the sequence listing information recorded in computer readable form (CRF) submitted herewith in the above-mentioned application is identical to the written sequence listing on CD-R (2 copies).

Respectfully submitted,

Jian S. Zhou

(Reg. No. 41,422)

Date: April 18, 200/

Patent Department, E2NA, Monsanto Company

800 N. Lindbergh Blvd.

St. Louis, MO 63167 Tel: (314) 694-3602

Fax: (314) 694-1671

